Manuscript Restructure Based on Reviewer Feedback: Clinical Challenges First, Platform Applications Last
Source type:
obs· Harvested: 2026-05-04 · Original date: 2026-05-04T09:19:50.323Z Metadata:{"project":"oncology-fih-research/oncology-fih-research","type":"decision","obs_id":65527}
obs/65527 · decision · 2026-05-04T09:19:50.323Z
Manuscript Restructure Based on Reviewer Feedback: Clinical Challenges First, Platform Applications Last
Reviewer feedback requested major restructuring of the FIH oncology landscape analysis manuscript to adopt a problem-solution narrative arc. The revised structure leads with current clinical development challenges in early-phase oncology trials, then presents the AI-driven ClinicalTrials.gov analysis as a data-driven solution for understanding global FIH trial patterns across investigators, sites, countries, and regions over the past 25 years. The manuscript must expand coverage of oncology drug modality evolution, particularly recent advances in ADC (antibody-drug conjugates), bispecific antibodies, T-cell engagers, and CAR-T therapies. Most significantly, the conclusion shifts from purely descriptive findings to emphasizing actionable platform applications: optimizing site selection for new trials, prioritizing global development plans to minimize competitive overlap, accelerating drug development by identifying opportunities to shorten FIH timelines, and ultimately reducing costs to bring first-in-class and best-in-class drugs to market faster. This reframing transforms the manuscript from a registry analysis into a strategic tool for oncology drug development decision-making.
Concepts: [“why-it-exists”,“what-changed”,“pattern”]
Facts: [“Reviewer requested manuscript restructure to begin with current clinical development challenges rather than data presentation”,“AI-driven FIH analysis repositioned as solution to global oncology trial landscape challenges across PI, site, country, region dimensions”,“Expanded coverage required for 25-year evolution of oncology drug types including ADC, bispecific antibodies, T-cell engagers, CAR-T therapies”,“Manuscript conclusion refocused on platform potential: site selection optimization, global development plan prioritization, competition minimization, FIH timeline acceleration, and cost reduction for first-in-class/best-in-class drug development”]
[← 回 Alfred Brain Hub]